Short, tissue-specific peptides proposed to regulate gene expression — the Khavinson series.
Peptide bioregulators are a distinct research program rather than a single indication: very short peptides — typically two to four amino acids — developed largely by the St. Petersburg Institute of Bioregulation and Gerontology (the "Khavinson" school). Each is associated with a specific tissue and is proposed to act not as a hormone or receptor ligand but as a direct regulator of gene expression in that tissue.
The series began with animal-tissue extracts (the "Cytomax" preparations such as Thymalin) and moved to defined synthetic short peptides (the "Cytogens" — Vilon, Epitalon, Vesugen, Pinealon, Bronchogen, Cardiogen, Pancragen). The central, still-debated hypothesis is that these peptides enter the cell, reach the nucleus, and bind sequence-specific promoter regions of DNA, switching on tissue-relevant genes that fall silent with age. Crucially, almost all clinical and lifespan data come from a single research tradition with limited independent Western replication — so this area is framed as preliminary and evidence-graded, not promotional. It is a research reference, not medical advice.
Synthetic tetrapeptide investigated for telomerase activity and circadian effects.
View profileThe natural pineal peptide bioregulator — the animal-derived counterpart to synthetic Epitalon, marketed for aging and telomere support.
View profileThymus-derived polypeptide complex — the founding tissue bioregulator (Cytomax) studied for immune restoration.
View profileA synthetic thymic dipeptide (Glu-Trp) immunomodulator — the minimal active fragment distilled from thymus peptides.
View profileSynthetic Lys-Glu dipeptide — the defined short-peptide successor to Thymalin, studied for immune and aging endpoints.
View profileSynthetic Lys-Glu-Asp tripeptide studied as a vascular-axis bioregulator.
View profileSynthetic Glu-Asp-Arg tripeptide studied as a brain/CNS bioregulator.
View profileSynthetic Ala-Asp-Glu-Leu tetrapeptide studied as a respiratory-tissue bioregulator.
View profileSynthetic Ala-Glu-Asp-Arg tetrapeptide studied as a cardiac-tissue bioregulator.
View profileSynthetic Lys-Glu-Asp-Trp tetrapeptide studied as a pancreas-tissue bioregulator.
View profileSynthetic Lys-Glu-Asp-Gly tetrapeptide studied as a testis / reproductive-tissue bioregulator.
View profileSynthetic Lys-Glu-Asp-Pro tetrapeptide studied as a prostate-tissue bioregulator — the defined-sequence successor to older prostate extracts.
View profileA natural thymus peptide complex (Cytomax A-6) — the extract-based counterpart to Thymalin, marketed for immune support and aging.
View profileA natural blood-vessel peptide complex (Cytomax A-3) — the extract-based counterpart to Vesugen, targeting vascular tissue.
View profileA natural heart-muscle peptide complex (Cytomax A-14) — the extract-based counterpart to Cardiogen, targeting cardiac tissue.
View profileA very short, tissue-specific peptide — usually 2 to 4 amino acids — from the Khavinson Cytomax/Cytogen series, proposed to regulate gene expression in a particular organ rather than act as a hormone or receptor ligand.
The class hypothesis is that the short peptide enters the cell, reaches the nucleus, and binds specific DNA promoter regions, modulating transcription in a tissue-selective way. This mechanism is proposed and partially supported in the originating literature, not firmly established by independent structural work.
Weaker and narrower than the popularity suggests. Most clinical and lifespan data come from a single research tradition with limited independent replication, so findings should be treated as preliminary.
Longevity is an indication (the aging endpoint); bioregulators is a class (short tissue-regulating peptides). Several members — Epitalon, Vilon, Vesugen — appear in both, framed by endpoint in one and by the shared bioregulator hypothesis here.
How to weigh this evidence
Preclinical, observational, and randomized findings carry very different weight. The evidence hierarchy shows how to rank what you read before drawing conclusions.
Put the science to work — interactive utilities that run right here.
Ask in plain language — citation-backed answers from PubMed, PubChem & trials.
Build a peptide residue by residue with live chemistry, challenges & XP.
Sequence properties — pI, ε280, net charge & synthesis-difficulty flags.
Paste a certificate of analysis; grade its transparency and spot red flags.
Dose, dilution and syringe-unit math for reconstituting a vial.
Verified peptide monographs plus a live PubChem compound lookup.
Which peptides are best studied for peptide bioregulators, how they compare, and what the clinical evidence shows — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.